Tianjin Biochemical Pharmaceutical Co., Ltd. is Tianjin Time-honored Brand enterprise, national high-tech company, founded in 1943, formerly known as Tianjin Biochemical Pharmaceutical Factory. The state-owned enterprise has more than seventy years of history focusing on research and development of biochemical and chemical pharmaceutical preparations. It has strong injection production experience and technology expertise, especially specializes in sterile injection production of non-final sterilization. The enterprise moved to Tianjin Airport Economic Zone at the end of 2005, and completed corporation restructuring in 2007. In 2010, it became a wholly-owned subsidiary of Tianjin Lisheng Pharmaceutical Co.,Ltd.
The company covers an area of 30,000 square meters, owning 6 high-standard production lines, which includes three dosage forms of lyophillized powder injection, small volume injection (water injection) and API. There are 48 product varieties involving the field of cardio-cerebrovascular, hormone, biochemistry, animal viscera extraction and plant extraction. The company's "Sheng Hua Brand" trademark is Tianjin famous brand and well-known in China. The main products are nadroparin calcium injection, hydrocortisone sodium succinate for injection, urokinase for injection, heparin sodium injection, heparin calcium injection and ocular extractives injection.
The company adheres to the business purposes of " Keeping the Foundation of Good Faith, being Good People to Make Quality Medicine ", persues the pharmaceutical spirit of "Profession and Focus, Delicacy and Fineness" , abides by the quality policy of "Quality First, Continuous Improvement" , sticks to standardized management on manufacturing site and quality control of each production process, has passed the national GMP inspection and international GMP audit. The company was rated as Class A enterprise for drug production (namely safe drug factory) by Tianjin Drug Administration for many consecutive years.
Facing the future, we will be in line with the development policy of "innovation to boost the enterprise, high quality to strengthen the enterprise, excellence to promote the enterprise" and continue to speed up the pace of technical innovation and transformation of scientific research achievements, increase our brand awareness and enhance enterprise core competitiveness, with a more robust pace to stick to green development, safe development and sustainable development, in order to push forward health in China and make new efforts and contributions to human health.
In the future , we will focus on “innovation , high quality production” to promote the enterprise into sound conditions , continue to speed up the pace of technical innovation and transformation of scientific research achievements , increasing our enterprises competitiveness , with a more robust pace to stick to green development , and make great efforts and contributions to the development of pharmaceutical industry.
Merged with Berlin Pharmaceutical Factory to become "Tianjin Public-Private Joint Venture Bohai Pharmaceutical Factory"
"Tianjin Biochemical Pharmaceutical Co.,Ltd."
Rename as "Tianjin Lixin Pharmaceutical Factory"
Renamed as "Tianjin Biochemical Pharmaceutical Factory"
Became a wholly-owned subsidiary of Tianjin Lisheng Pharmaceutical Co.,Ltd.
In 2010, Tianjin Biochemical Pharmaceutical Co.,Ltd. became a wholly-owned subsidiary of Tianjin Lisheng Pharmaceutical Co.,Ltd., which is a large pharmaceutical enterprise in Tianjin, it was founded in 1951, business scale covers Chinese and western medicine tablets, hard capsules, granules, dropping pills and API. Sales network cover the whole country, some products are exported to Japan, Australia, South Korea, Europe, the United States, Southeast Asian countries and regions.